Cholangitis - 54 Studies Found
| Completed |
: Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis : Primary Sclerosing Cholangitis (PSC) : 2014-02-11 : Drug: LUM001 LUM001 oral dose |
| Recruiting |
: Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures : Primary Sclerosing Cholangitis : 2015-12-09 : Device: probe based confocal laser endomicroscopy real-time, microscopic imaging of tissue at the cellul |
| NOT_YET_RECRUITING |
: CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) : : 2024-11-22 : Oral QD |
| NOT_YET_RECRUITING |
: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) : : 2024-11-22 : Oral QD |
| RECRUITING |
: Detoxification of the Liver In PSC (Dolphin) : Primary Sclerosing Cholangitis : 2024-11-22 : Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will rec |
| RECRUITING |
: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis : Primary Biliary Cholangitis : 2024-11-22 : Seladelpar 10 mg one capsule daily for up to 36 months. |
| RECRUITING |
: Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach : Primary Sclerosing Cholangitis : 2024-11-22 |
| RECRUITING |
: Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study : Primary Sclerosing Cholangitis : 2024-11-22 : Rosuvastatin 20 mg tablet once daily by mouth |
| RECRUITING |
: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis : Primary Biliary Cholangitis (PBC) : 2024-11-22 : Duration: up to an estimated 84-month (7-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily |
| RECRUITING |
: IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) : Primary Biliary Cholangitis : 2024-11-22 : Seladelpar 10 mg one capsule daily for up to 52 weeks |